Year: 2020

news_6

JS InnoPharm Announces First Patient Dosed with JSI-1187, a Selective ERK Inhibitor, in Phase 1 Clinical Study for Advanced Solid Tumors with MAPK Pathway Mutations

CHICAGO & SHANGHAI--(BUSINESS WIRE)--JS InnoPharm Ltd today announced the enrollment of the first patient in a Phase 1, open-label, monotherapy...